{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BIC", "query": { "intervention": "BIC" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 40, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BIC&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T07:45:45.504Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02397694", "title": "Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "BIC", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" }, { "name": "BIC Placebo", "type": "DRUG" }, { "name": "DTG Placebo", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2015-03-23", "completion_date": "2019-02-27", "has_results": true, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-09-02T07:45:45.504Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02397694" }, { "nct_id": "NCT04530630", "title": "Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections", "Renal Transplant Rejection" ], "interventions": [ { "name": "BIC/F/TAF 50Mg-200Mg-25Mg Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-11-09", "completion_date": "2024-08-28", "has_results": true, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-09-02T07:45:45.504Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04530630" }, { "nct_id": "NCT04143594", "title": "Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Oral Lenacapavir", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "Subcutaneous Lenacapavir", "type": "DRUG" }, { "name": "TAF", "type": "DRUG" }, { "name": "BIC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2019-11-22", "completion_date": "2023-09-19", "has_results": true, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-09-02T07:45:45.504Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04143594" }, { "nct_id": "NCT06532656", "title": "Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Lenacapavir", "type": "DRUG" }, { "name": "BIC/LEN FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 75, "start_date": "2024-11-20", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-02T07:45:45.504Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Atlanta, Georgia + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06532656" }, { "nct_id": "NCT04233879", "title": "Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "DOR/ISL", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to DOR/ISL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 599, "start_date": "2020-02-28", "completion_date": "2025-01-29", "has_results": true, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-02T07:45:45.504Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04233879" }, { "nct_id": "NCT06596044", "title": "Suicide Prevention After Community Care Discharge", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Suicide Prevention" ], "interventions": [ { "name": "VA BIC", "type": "BEHAVIORAL" }, { "name": "Standard Care", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-10-01", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-09-02T07:45:45.504Z", "location_count": 1, "location_summary": "White River Junction, Vermont", "locations": [ { "city": "White River Junction", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT06596044" }, { "nct_id": "NCT04039217", "title": "Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "ART", "HIV" ], "interventions": [ { "name": "Biktarvy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "MALE", "summary": "18 Years to 49 Years · Male only" }, "enrollment_count": 20, "start_date": "2019-09-30", "completion_date": "2020-08-28", "has_results": true, "last_update_posted_date": "2022-02-22", "last_synced_at": "2026-09-02T07:45:45.504Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04039217" }, { "nct_id": "NCT07476339", "title": "REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV -1 Infection", "HIV (Human Immunodeficiency Virus)", "HIV", "HIV 1 Infection" ], "interventions": [ { "name": "Bictegravir, emtricitabine, and tenofovir alafenamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CAN Community Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2026-06-17", "completion_date": "2027-06-17", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-02T07:45:45.504Z", "location_count": 10, "location_summary": "Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07476339" }, { "nct_id": "NCT06891066", "title": "A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus Type 1 (HIV-1) Infection" ], "interventions": [ { "name": "ISL", "type": "DRUG" }, { "name": "ULO", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-04-14", "completion_date": "2031-09-30", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-02T07:45:45.504Z", "location_count": 11, "location_summary": "San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06891066" }, { "nct_id": "NCT04446468", "title": "Suicide Prevention Study of VA-BIC in the Veteran Population", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Suicide Prevention" ], "interventions": [ { "name": "PEACE", "type": "BEHAVIORAL" }, { "name": "Standard Psychiatric Hospital Discharge Care", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2021-03-19", "completion_date": "2025-09-25", "has_results": true, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-09-02T07:45:45.504Z", "location_count": 1, "location_summary": "White River Junction, Vermont", "locations": [ { "city": "White River Junction", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT04446468" } ] }